IN8bio (INAB) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 03, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Registrant Name	IN8BIO, INC.
Entity Central Index Key	0001740279
Entity Tax Identification Number	82-5462585
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-39692
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	350 5th Avenue
Entity Address, Address Line Two	Suite 5330
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10118
City Area Code	646
Local Phone Number	600-6438
Trading Symbol	INAB
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		18,838,471
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash	$ 32,107	$ 37,021
Prepaid expenses and other current assets	1,167	1,959
Total Current Assets	33,274	38,980
Non-current assets
Property and equipment, net	240	97
Construction in progress	497	403
Restricted Cash	251	251
Right of use assets - financing leases	555	704
Right of use assets - operating leases	1,563	1,630
Other non-current assets	158	158
Total Non-Current Assets	3,264	3,243
Total Assets	36,538	42,223
Current liabilities
Accounts payable	553	395
Accrued expenses and other current liabilities	884	1,235
Short-term financing lease liability	325	392
Short-term operating lease liability	306	234
Total Current Liabilities	2,068	2,256
Long-term financing lease liability	201	269
Long-term operating lease liability	1,434	1,515
Total Non-Current Liabilities	1,635	1,784
Total Liabilities	3,703	4,040
Commitments and Contingencies
Stockholders' Deficit
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at March 31, 2022 and December 31, 2021; 18,812,267 and 18,781,242 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	2	2
Additional paid-in capital	71,669	70,872
Accumulated deficit	(38,836)	(32,691)
Total Stockholders' Equity	32,835	38,183
Total Liabilities and Stockholders' Equity	$ 36,538	$ 42,223

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares, issued	18,812,267	18,781,242
Common stock, shares, outstanding	18,812,267	18,781,242

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 2,381	$ 1,245
General and administrative	3,764	1,118
Total operating expenses	6,145	2,363
Loss from operations	(6,145)	(2,363)
Net loss	(6,145)	(2,363)
Net loss attributable to common stockholders (Note 10)	$ (6,145)	$ (3,069)
Net loss per share attributable to common stockholders – basic and diluted	$ (0.33)	$ (0.82)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	18,800,546	3,764,488

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Temporary equity shares beginning at Dec. 31, 2020		9,993,727
Temporary equity amount beginning at Dec. 31, 2020		$ 34,900
Shares beginning at Dec. 31, 2020			3,764,488
Balance beginning at Dec. 31, 2020	$ (16,579)		$ 1	$ 1,458	$ (18,038)
Stock-based compensation expense	361			361
Net loss	(2,363)				(2,363)
Temporary equity shares ending at Mar. 31, 2021		9,993,727
Temporary equity amount ending at Mar. 31, 2021		$ 34,900
Shares ending at Mar. 31, 2021			3,764,488
Balance ending at Mar. 31, 2021	(18,581)		$ 1	1,819	(20,401)
Shares beginning at Dec. 31, 2021			18,781,242
Balance beginning at Dec. 31, 2021	38,183		$ 2	70,872	(32,691)
Conversion of convertible preferred stock to common stock, shares			31,025
Conversion of convertible preferred stock to common stock	33			33
Stock-based compensation expense	764			764
Net loss	(6,145)				(6,145)
Shares ending at Mar. 31, 2022			18,812,267
Balance ending at Mar. 31, 2022	$ 32,835		$ 2	$ 71,669	$ (38,836)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (6,145)	$ (2,363)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	16	22
Non-cash stock-based compensation	764	361
Amortization of financing lease right-of-use assets	149	113
Amortization of operating lease right-of-use assets	67	30
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	792	(162)
Other current assets		(52)
Accounts payable	158	(180)
Accrued expenses and other current liabilities	(351)	(298)
Short-term operating lease liabilities	72	57
Long-term operating lease liabilities	(81)	(35)
Net cash used in operating activities	(4,559)	(2,507)
Investing activities
Purchases of property and equipment	(8)
Construction in progress	(245)
Net cash used in investing activities	(253)
Financing activities
Principal payments on financing leases	(135)	(112)
Exercise of common stock	33
Deferred offering costs paid		(323)
Net cash provided by financing activities	(102)	(435)
Net increase in cash and restricted cash	(4,914)	(2,942)
Cash and restricted cash at beginning of period	37,272	17,994
Cash and restricted cash at end of period	32,358	15,052
Cash, end of period	32,107	15,052
Restricted cash, end of period	251
Cash and restricted cash, end of period	32,358	15,052
Supplemental disclosure of non-cash operating, financing and investing information
Deferred offering costs included in accounts payable and accrued expenses		1,238
Initial measurement of operating lease right-of-use assets and liabilities		$ 3,483

Organization and Nature of Oper

Organization and Nature of Operations	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	1. ORGANIZATION AND NATURE OF OPERATIONS Organization and Business IN8bio, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The Company’s lead product candidates are currently in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed glioblastoma (“GBM”), and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic stem cell transplantation (“HSCT”). In addition, the Company’s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-300 and INB-400, focused on addressing other solid tumor types. Incysus, Inc. (“Incysus”) was a corporation formed in the State of Delaware on November 23, 2015 and Incysus, Ltd. was incorporated in Bermuda on February 8, 2016. Incysus was the wholly owned United States subsidiary of Incysus, Ltd. On May 7, 2018, Incysus, Ltd. reincorporated in the United States in a domestication transaction (the “Domestication”) in which Incysus, Ltd. converted into a newly formed Delaware corporation, Incysus Therapeutics, Inc. (“Incysus Therapeutics”). On July 24, 2019, Incysus Therapeutics merged with Incysus. Incysus Therapeutics subsequently changed its name to IN8bio, Inc. in August 2020. Following the Domestication in May 2018 and the merging of Incysus Therapeutics and Incysus in July 2019, the Company does not have any subsidiaries to consolidate. The Company is headquartered in New York, New York. Coronavirus Pandemic Th e ongoing COVID-19 pandemic, including the periods of resurgences of cases relating to the spread of various strains such as the Delta and Omicron variants, has had a significant impact, both direct and indirect, on businesses and commerce, as certain worker shortages have occurred, supply chains have been disrupted, and facilities and productions have been suspended. The COVID-19 pandemic has impacted and may continue to impact the clinical sites and startup activities for the Company’s Phase 1/2 clinical trial, including third-party manufacturing and logistics providers, which have disrupted and may continue to disrupt its supply chains and the availability or cost of materials, and it has affected and may continue to affect the Company’s ability to timely initiate, enroll and complete its clinical trials, conduct regulatory activities and operate its business more generally. The pandemic may impact the timing of regulatory approval of the investigational new drug application for clinical trials, the enrollment of any clinical trials that are approved, the availability of clinical trial materials and regulatory approval and commercialization of our products. The pandemic may also continue to impact the capital markets, inflation expectations and the Company’s ability to access capital, which could negatively impact short-term and long-term liquidity. The full extent to which the pandemic may impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including as a result of evolving variants of COVID-19, the duration and intensity of the related effects of the pandemic and the uncertainty of the timing of the broader economic recovery to pre-pandemic levels. Initial Public Offering On August 3, 2021 , the Company completed its initial public offering (“IPO”) in which it issued and sold 4,000,000 shares of its common stock at a public offering price of $ 10.00 per share. The Company received net proceeds from the IPO of $ 32.3 million, after deducting underwriters’ discounts, commissions, and offering-related costs. Upon closing of the IPO, all of the Company's outstanding shares of convertible preferred stock automatically converted into 10,990,065 shares of common stock (see Note 7) Liquidity and Capital Resources Through March 31, 2022 , the Company funded its operations primarily with proceeds from its Series A convertible preferred stock financing (“Series A Financing”) and with proceeds from its IPO. The Company has incurred recurring losses and negative operating cash flows from operations since its inception, including net losses of $ 6.1 million and $ 2.4 million for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022 , the Company had an accumulated deficit of $ 38.8 million. The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future to conduct research and development and will need to raise additional capital to fully implement management’s business plan. The Company intends to raise such capital through the issuance of additional equity, and potentially through borrowings, strategic alliances with partner companies and other licensing transactions. However, if such financing is not available at adequate levels, the Company may need to reevaluate its operating plans. Management believes that its existing cash of $ 32.1 million as of March 31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these condensed financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2021 and the notes thereto are included in the Company’s Annual Report on Form 10-K (the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 17, 2022. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies except as noted below. Basis of Presentation The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States (“US GAAP”). Un audited Interim Financial Information The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Company's Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. Use of Estimates The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and related valuation allowance, fair value of common stock and stock-based compensation, and the useful lives of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. The estimated useful lives of the Company’s respective assets are as follows: Estimated Useful Life Computer equipment 3 years Furniture 7 years Laboratory equipment 3 - 5 years Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation are removed from the balance sheet and any gain or loss is reflected in the statement of operations. Recently Issued Accounting Standards Updates In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting of Income Taxes ("Topic 740"), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021, with early adoption permitted. The Company has evaluated this guidance and determined that it does not have a material impact to its condensed financial statements.

Property And Equipment, Net

Property And Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	3. PROPERTY AND EQUIPMENT, NET Property and equipment, net consist of the following (in thousands): March 31, December 31, Machinery and equipment $ 451 $ 443 Furniture and fixtures 151 — Less accumulated depreciation ( 362 ) ( 346 ) Property and equipment, net $ 240 $ 97 Depreciation expense was $ 16 ,000 and $ 22 ,000 for the three months ended March 31, 2022 and 2021 , respectively.

Construction in Progress

Construction in Progress	3 Months Ended
	Mar. 31, 2022
Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]
Construction in Progress	4. CONSTRUCTION IN PROGRESS Construction in progress consist of the following (in thousands): March 31, December 31, Furniture $ 3 $ 77 Leasehold improvements 368 200 Internal use software not yet in service 126 126 Construction in progress $ 497 $ 403

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following (in thousands): March 31, December 31, Accrued clinical trials $ 206 $ 196 Accrued compensation 318 926 Accrued other 360 113 Total accrued expenses and other current liabilities $ 884 $ 1,235

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
DEBT	6. Debt In April 2020, the Company was granted a loan (the “Loan”) in an amount of $ 0.2 million, pursuant to the Paycheck Protection Program under Division A, Title I of the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, which was enacted on March 27, 2020. The Loan, which was in the form of a Note dated April 16, 2020, was scheduled to mature on April 16, 2022 and bore interest at a rate of 1.0 % per annum, payable monthly commencing on November 16, 2020 . The Loan could be prepaid by the Company at any time prior to maturity with no prepayment penalties. The Company used the entire Loan amount for qualifying expenses. In August 2021, the Company repaid the Loan of $ 0.2 million in full.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity (Deficit)	7. Stockholders' Equity Convertible Preferred Stock Upon closing of the IPO, all of the Company's outstanding shares of convertible preferred stock automatically converted into 10,990,065 shares of common stock.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	8. STOCK-BASED COMPENSATION 2018 Equity Incentive Plan On May 7, 2018, the Company established and adopted the 2018 Equity Incentive Plan (the “2018 Plan”) providing for the granting of stock awards for employees, directors and consultants to purchase shares of the Company’s common stock. Upon the effectiveness of the 2020 Plan (as defined below), the plan was terminated and no further issuances were made under the 2018 Plan, although it continues to govern the terms of any equity grants that remain outstanding under the 2018 Plan. 2020 Equity Incentive Plan The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Board of Directors and the Company’s stockholders and became effective on July 29, 2021. The Board of Directors, or committee thereof, is authorized to administer the 2020 Plan. The 2020 Plan provides for the grant of incentive stock options (“ISOs”) within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986, as amended, to employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants and any affiliates’ employees and consultants. The number of shares initially reserved for issuance under the 2020 Plan was 4,200,000 , which will automatically increase on January 1 of each year for a period of 10 years , beginning on January 1, 2022 and continuing through January 1, 2031, in an amount equal to 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding year, or a lesser number of shares determined by the Board of Directors no later than the last day of the immediately preceding year. The maximum number of shares of common stock that may be issued upon the exercise of ISOs under the 2020 Plan will be 13,000,000 shares. On January 1, 2022, the shares reserved for issuance was increased to 5,139,062 4,401,211 shares were available for grant pursuant to the 2020 Plan. 2020 Employee Stock Purchase Plan The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s Board of Directors and the Company’s stockholders and became effective on July 29, 2021. A total of 200,000 shares of common stock were initially reserved for issuance under this plan, which will automatically increase on January 1 of each year for a period of 10 years , beginning on January 1, 2021 and continuing through January 1, 2031, by the lesser of 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding year; and 400,000 shares, except before the date of any such increase, the Board of Directors may determine that such increase will be less than the amount set forth above. As of December 31, 2021 , no shares of common stock had been issued under the 2020 ESPP and 200,000 shares remained available for future issuance under the 2020 ESPP. On January 1, 2022, the shares reserved for issuance was increased to 387,812 shares. The first offering period has not yet been decided by the Company’s Board of Directors or designated committee of the Company’s Board of Directors. Stock Option Activity The following is a summary of the stock option award activity during the three months ended March 31, 2022: Number Weighted- Weighted- Aggregate Outstanding at December 31, 2021 2,306,379 $ 6.51 8.99 $ 983 Granted 801,600 4.10 Exercised ( 31,025 ) 1.07 Forfeited ( 63,749 ) 6.83 Outstanding at March 31, 2022 3,013,205 $ 5.91 9.05 $ 620 Exercisable at March 31, 2022 665,794 $ 5.64 8.31 $ 363 Options expected to vest as of March 31, 2022 2,347,411 $ 5.98 9.26 $ 257 The weighted-average grant date fair value of options granted during the three months ended March 31, 2022 and 2021 is $ 4.10 and $ 4.02 , respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the market price of the Company’s common stock at March 31, 2022. The aggregate intrinsic value of stock options exercised in the three months ended March 31, 2022 was $ 0.1 million. Stock-Based Compensation Expense For the three months ended March 31, 2022 and 2021 , the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options. The following table presents the assumptions and the Company’s methodology for developing each of the assumptions used: March 31, March 31, Volatility 87.13 % 88.8 % Expected life (years) 6.08 6.08 Risk-free interest rate 2.01 % 0.7 % Dividend rate — — • Volatility—The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the expected term. • Expected life—The expected term represents the period that the Company’s stock option grants are expected to be outstanding. The expected term of the options granted to employees and non-employee directors by the Company has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. • Risk-free interest rate—The risk-free rate for periods within the estimated life of the stock award is based on the U.S. Treasury yield curve in effect at the time of grant. • Dividend rate—The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Research and development $ 294 $ 168 General and administrative 470 193 Total stock-based compensation expense $ 764 $ 361 No related tax benefits from stock-based compensation expense were recognized for the three months ended March 31, 2022 and 2021. As of March 31, 2022 , there was $ 9.6 million in unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of 3.19 years.

License Agreements

License Agreements	3 Months Ended
	Mar. 31, 2022
License Agreements [Abstract]
License Agreements	9. LICENSE AGREEMENTS Emory University, Children’s Healthcare of Atlanta, Inc. and UAB Research Foundation In June 2016, the Company entered into an exclusive license agreement with Emory University, Children’s Healthcare of Atlanta, Inc. and UAB Research Foundation ("UABRF"), as amended from time to time (the “Emory License Agreement”). The Emory License Agreement was amended in October 2017 and July 2020. Under the Emory License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy related patents and know-how related to gamma-delta T cells developed by Emory University, Children’s Healthcare of Atlanta, Inc. and UABRF’s affiliate, the University of Alabama at Birmingham, to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents or otherwise incorporate or use the licensed technology. Such exclusive license is subject to certain rights retained by these institutions and also the U.S. government. In consideration of the license granted under the Emory License Agreement, the Company paid Emory University a nominal upfront payment. In addition, the Company is required to pay Emory University development milestones totaling up to an aggregate of $ 1.4 million, low-single-digit to mid-single-digit tiered running royalties on the net sales of the licensed products, including an annual minimum royalty beginning on a specified period after the first sale of a licensed product, and a share of certain payments that the Company may receive from sublicenses. In addition, in the event no milestone payments have been paid in certain years, the Company will be required to pay an annual license maintenance fee. The Emory License Agreement also requires the Company to reimburse Emory University for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the Emory License Agreement, the Company is required to use its best efforts to develop, manufacture and commercialize the licensed product, and is obligated to meet certain specified deadlines in the development of the licensed products. The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later. The Company may terminate the Emory License Agreement at will at any time upon prior written notice to Emory University. Emory University has the right to terminate the Emory License Agreement if the Company materially breaches the agreement (including failure to meet diligence obligations) and fails to cure such breach within a specified cure period, if the Company becomes bankrupt or insolvent or decides to cease development and commercialization of the licensed product, or if the Company challenges the validity or enforceability of any licensed patents. Exclusive License Agreement with UABRF In March 2016, the Company entered into an exclusive license agreement with UABRF, as amended from time to time (the “UABRF License Agreement”). The Company amended the UABRF License Agreement in December 2016, January 2017, June 2017 and November 2018. Under the UABRF License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy-related patents related to the use of gamma-delta T cells, certain CAR-T cells and combination treatments for cellular therapies developed by the University of Alabama at Birmingham and owned by UABRF to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents. Such exclusive license is subject to certain rights retained by UABRF and also the U.S. government. In consideration of the license granted under the UABRF License Agreement, the Company paid UABRF a nominal upfront payment and issued 91,250 shares of common stock to UABRF, which were subject to certain antidilution rights. In addition, the Company is required to pay UABRF development milestones totaling up to an aggregate of $ 1.4 million, lump-sum royalties on cumulative net sales totaling up to an aggregate of $ 22.5 million, mid-single-digit running royalties on net sales of the licensed products, low-single-digit running royalties on net sales of the licensed products, and a share of certain non-royalty income that the Company may receive, including from any sublicenses. The UABRF License Agreement also requires the Company to reimburse UABRF for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the UABRF License Agreement, the Company is required to use good faith reasonable commercial efforts to develop, manufacture and commercialize the licensed product. The term of the UABRF License Agreement will continue until the expiration of the licensed patents. The Company may terminate the UABRF License Agreement at will at any time upon prior written notice to UABRF. UABRF has the right to terminate the UABRF License Agreement if the Company materially breaches the agreement and fails to cure such breach within a specified cure period, if the Company fails to diligently undertake development and commercialization activities as set forth in the development and commercialization plan, if the Company underreports its payment obligations or underpays by more than a specified threshold, if the Company challenges the validity or enforceability of any licensed patents, or if the Company becomes bankrupt or insolvent. Antidilution Provision The antidilution provision required the Company to issue additional shares of common stock such that UABRF maintains a 2.5 % ownership interest in the Company until it has raised at least $ 20.0 million through one or more rounds of investment. As of March 31, 2022 , the Company had a total of 151,382 shares of common stock issued in satisfaction of this antidilution provision.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	10. NET LOSS PER SHARE Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company. Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts): Three Months Ended 2022 2021 Net loss $ ( 6,145 ) $ ( 2,363 ) Cumulative dividends on convertible preferred stock — ( 706 ) Net loss attributable to common stockholders $ ( 6,145 ) $ ( 3,069 ) Net loss per share—basic and diluted $ ( 0.33 ) $ ( 0.82 ) Weighted-average number of shares used in computing net loss 18,800,546 3,764,488 The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is antidilutive: Three Months Ended 2022 2021 Convertible preferred stock — 9,993,727 Stock options to purchase common stock 3,013,205 1,552,290

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	11. COMMITMENTS AND CONTINGENCIES Intellectual Property The Company has existing commitments to the licensors of the intellectual property which the Company has licensed. These commitments are based upon certain clinical research, regulatory, financial and sales milestones being achieved. Additionally, the Company is obligated to pay a single-digit royalty on commercial sales on a global basis. The royalty term is the later of 10 years from first commercial sale or expiration of the last-to-expire component of the licensed intellectual property. Legal Proceedings The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluated whether or not a potential loss amount or potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expense as incurred costs related to such legal proceedings.

Facility Leases

Facility Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	12. Facility LEASES The Company has historically entered into lease arrangements for its facilities. As of March 31, 2022, the Company had three operating leases with required future minimum payments. In applying the transition guidance under Accounting Standards Codification (“ASC”) 842, Leases , the Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options. Finance Leases The Company entered into an agreement with an equipment leasing company in 2018, which provided up to $ 1.4 million for equipment purchases in the form of sale and leasebacks or direct leases. As of March 31, 2022 , the Company had completed the sale and leaseback for four pieces of equipment and is leasing three other items directly from the leasing company. The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment. The equipment leases require two advance rental payments to be held as security deposits. The security deposits held amounted to approximately $ 0.1 million as of March 31, 2022 and December 31, 2021. They are included in restricted cash on the condensed balance sheets. Operating Leases The Company has an operating lease for office space in Birmingham, Alabama, for a 63-month term, ending in March 2026, with an option to extend five years . Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The Company has an operating lease for office space in New York, New York, with a term commencing on September 15, 2021 and continuing through March 2027 . Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The Company has a build-to-suit lease agreement with a third party to build out the Company's labs in Birmingham Alabama. The agreement has a threshold of $ 4.0 million in total costs incurred. As of March 31, 2022 , $ 0.4 million in costs have been incurred and are classified as construction in progress on the condensed balance sheets. The operating leases require security deposits at the inception of each lease. The security deposits amounted to approximately $ 17,000 and $ 251,000 as of March 31, 2022 and December 31, 2021, respectively, and are included in other non-current assets and restricted cash on the condensed balance sheets, respectively. The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s finance and operating leases for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Lease Cost Amortization of finance right-of-use assets $ 149 $ 113 Interest on finance lease liabilities 14 21 Operating lease cost 112 52 Short-term lease cost 105 115 Total lease cost $ 380 $ 301 March 31, Other Operating Lease Information Cash paid for amounts included in the measurement of lease liability – finance leases $ 163 Cash paid for amounts included in the measurement of lease liability – operating leases 54 Weighted-average remaining lease term – finance leases 1.61 Weighted-average remaining lease term – operating leases 4.50 Weighted-average discount rate – finance leases 10.2 % Weighted-average discount rate – operating leases 10.4 % The following table reconciles the undiscounted cash flows to the operating and financing lease liabilities at March 31, 2022 (in thousands): Financing Leases Operating Leases Remainder of 2022 $ 286 $ 351 2023 252 478 2024 30 490 2025 — 502 2026 — 311 Thereafter — 45 Total lease payment 568 2,177 Less: interest 42 437 Total lease liabilities $ 526 $ 1,740 Less: Short-term lease liability 325 306 Long-term lease liability 201 1,434

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2021 and the notes thereto are included in the Company’s Annual Report on Form 10-K (the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 17, 2022. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies except as noted below.
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States (“US GAAP”).
Unaudited Interim Financial Information	Un audited Interim Financial Information The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto in the Company's Annual Report. The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and related valuation allowance, fair value of common stock and stock-based compensation, and the useful lives of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. The estimated useful lives of the Company’s respective assets are as follows: Estimated Useful Life Computer equipment 3 years Furniture 7 years Laboratory equipment 3 - 5 years Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or disposal of property and equipment, the cost and related accumulated depreciation are removed from the balance sheet and any gain or loss is reflected in the statement of operations.
Recently Issued Accounting Standards Updates	Recently Issued Accounting Standards Updates In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting of Income Taxes ("Topic 740"), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021, with early adoption permitted. The Company has evaluated this guidance and determined that it does not have a material impact to its condensed financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Property and Equipment	Significant replacements and improvements are capitalized, while maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. The estimated useful lives of the Company’s respective assets are as follows: Estimated Useful Life Computer equipment 3 years Furniture 7 years Laboratory equipment 3 - 5 years

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): March 31, December 31, Machinery and equipment $ 451 $ 443 Furniture and fixtures 151 — Less accumulated depreciation ( 362 ) ( 346 ) Property and equipment, net $ 240 $ 97

Construction in Progress (Table

Construction in Progress (Tables)	3 Months Ended
	Mar. 31, 2022
Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]
Schedule of construction in progress	Construction in progress consist of the following (in thousands): March 31, December 31, Furniture $ 3 $ 77 Leasehold improvements 368 200 Internal use software not yet in service 126 126 Construction in progress $ 497 $ 403

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): March 31, December 31, Accrued clinical trials $ 206 $ 196 Accrued compensation 318 926 Accrued other 360 113 Total accrued expenses and other current liabilities $ 884 $ 1,235

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Award Activity	The following is a summary of the stock option award activity during the three months ended March 31, 2022: Number Weighted- Weighted- Aggregate Outstanding at December 31, 2021 2,306,379 $ 6.51 8.99 $ 983 Granted 801,600 4.10 Exercised ( 31,025 ) 1.07 Forfeited ( 63,749 ) 6.83 Outstanding at March 31, 2022 3,013,205 $ 5.91 9.05 $ 620 Exercisable at March 31, 2022 665,794 $ 5.64 8.31 $ 363 Options expected to vest as of March 31, 2022 2,347,411 $ 5.98 9.26 $ 257
Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted	The following table presents the assumptions and the Company’s methodology for developing each of the assumptions used: March 31, March 31, Volatility 87.13 % 88.8 % Expected life (years) 6.08 6.08 Risk-free interest rate 2.01 % 0.7 % Dividend rate — —
Schedule of Stock-based Compensation Expense	Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Research and development $ 294 $ 168 General and administrative 470 193 Total stock-based compensation expense $ 764 $ 361

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts): Three Months Ended 2022 2021 Net loss $ ( 6,145 ) $ ( 2,363 ) Cumulative dividends on convertible preferred stock — ( 706 ) Net loss attributable to common stockholders $ ( 6,145 ) $ ( 3,069 ) Net loss per share—basic and diluted $ ( 0.33 ) $ ( 0.82 ) Weighted-average number of shares used in computing net loss 18,800,546 3,764,488
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is antidilutive: Three Months Ended 2022 2021 Convertible preferred stock — 9,993,727 Stock options to purchase common stock 3,013,205 1,552,290

Facility Leases (Tables)

Facility Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Summary of Lease Costs and Other Information to Company's Finance and Operating Liabilities	The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s finance and operating leases for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended 2022 2021 Lease Cost Amortization of finance right-of-use assets $ 149 $ 113 Interest on finance lease liabilities 14 21 Operating lease cost 112 52 Short-term lease cost 105 115 Total lease cost $ 380 $ 301 March 31, Other Operating Lease Information Cash paid for amounts included in the measurement of lease liability – finance leases $ 163 Cash paid for amounts included in the measurement of lease liability – operating leases 54 Weighted-average remaining lease term – finance leases 1.61 Weighted-average remaining lease term – operating leases 4.50 Weighted-average discount rate – finance leases 10.2 % Weighted-average discount rate – operating leases 10.4 %
Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Financing Lease Liabilities	The following table reconciles the undiscounted cash flows to the operating and financing lease liabilities at March 31, 2022 (in thousands): Financing Leases Operating Leases Remainder of 2022 $ 286 $ 351 2023 252 478 2024 30 490 2025 — 502 2026 — 311 Thereafter — 45 Total lease payment 568 2,177 Less: interest 42 437 Total lease liabilities $ 526 $ 1,740 Less: Short-term lease liability 325 306 Long-term lease liability 201 1,434

Organization and Nature of Op_2

Organization and Nature of Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 03, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Organization And Nature Of Operations [Line Items]
Losses from operations		$ 6,145	$ 2,363
Accumulated deficit		(38,836)		$ (32,691)
Cash		32,107	15,052	$ 37,021
IPO [Member]
Organization And Nature Of Operations [Line Items]
Sale of stock, date	Aug. 3, 2021
Sale of shares	4,000,000
Offering price, per share	$ 10
Aggregate net proceeds from offering	$ 32,300
Conversion of convertible preferred stock to common stock, shares	10,990,065
Series A Financing
Organization And Nature Of Operations [Line Items]
Losses from operations		(6,100)	$ (2,400)
Accumulated deficit		$ 38,800

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Significant Accounting Policies [Line Items]
Lease liabilities	$ 1,740
Right-of-use assets	$ 1,563	$ 1,630

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)	3 Months Ended
	Mar. 31, 2022
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Property And Equipment, Net - S

Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Less accumulated depreciation	$ (362)	$ (346)
Construction in progress	497	403
Property and equipment, net	240	97
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	151
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 451	$ 443

Property And Equipment, Net - A

Property And Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 16	$ 22

Construction in Progress - Sche

Construction in Progress - Schedule of Construction In Progress (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Public Utilities, Property, Plant and Equipment, Plant in Service [Abstract]
Furniture	$ 3	$ 77
Leasehold improvements	368	200
Internal use software not yet in service	126	126
Construction in progress	$ 497	$ 403

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued clinical trials	$ 206	$ 196
Accrued compensation	318	926
Accrued other	360	113
Total accrued expenses and other current liabilities	$ 884	$ 1,235

Debt - Additional Information (

Debt - Additional Information (Details) - Paycheck Protection Program [Member] - USD ($)	1 Months Ended
	Aug. 31, 2021	Apr. 30, 2020
Debt Instrument [Line Items]
Loan		$ 200
Loan maturity, date		Apr. 16, 2022
Interest Rate		1.00%
Debt instrument, Payment terms		monthly
Debt instrument, Date of first required payment		Nov. 16, 2020
Prepayment penalties		$ 0
Repayment of loan	$ 200,000

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) - Additional Information (Details) - shares	Aug. 03, 2021	Mar. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Common stock, shares authorized		490,000,000	490,000,000
Common stock, shares, issued		18,812,267	18,781,242
Common stock, shares, outstanding		18,812,267	18,781,242
IPO [Member]
Class Of Stock [Line Items]
Conversion of convertible preferred stock to common stock, shares	10,990,065

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	Jul. 29, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Weighted average grant-date fair value of options granted		$ 4.10	$ 4.02
Tax benefit from stock based compensation expense		$ 0	$ 0
Aggregate intrinsic value of stock options exercised		100,000
Share-based payment arrangement, unrecognized stock based compensation cost		$ 9,600,000
Weighted-average period over which cost not yet recognized is expected to be recognized		3 years 2 months 8 days
2020 Equity Incentive Plan
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Common stock reserved for future issuance	4,200,000
Shares reserved of issuance under the plan increase duration	10 years
Percentage of number of shares of common stock outstanding	5.00%
Maximum number of shares of common stock issuable	13,000,000
Share-based payment award, number of shares available for grant		4,401,211
2020 Equity Incentive Plan | January 1, 2022
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Common stock reserved for future issuance		5,139,062
2020 Employee Stock Purchase Plan
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Share-based payment award, shares issued in period				0
Common stock reserved for future issuance	200,000
Shares reserved of issuance under the plan increase duration	10 years
Percentage of number of shares of common stock outstanding	1.00%
Maximum number of shares of common stock issuable	400,000
Share-based payment award, number of shares available for grant				200,000
2020 Employee Stock Purchase Plan | January 1, 2022
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Common stock reserved for future issuance		387,812

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock Option Award Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Options outstanding, beginning balance	2,306,379
Options granted	801,600
Options exercised	(31,025)
Options forfeited	(63,749)
Options outstanding, ending balance	3,013,205	2,306,379
Options exercisable	665,794
Options vested or expected to vest	2,347,411
Options outstanding, weighted average exercise price, beginning balance	$ 6.51
Options granted, weighted average exercise price	4.10
Options exercised, weighted average exercise price	1.07
Options forfeited, weighted average exercise price	(6.83)
Options outstanding, weighted average exercise price, ending balance	5.91	$ 6.51
Options exercisable, weighted average exercise price	5.64
Options vested or expected to vest, weighted average exercise price	$ 5.98
Options outstanding, weighted average remaining contractual term	9 years 18 days	8 years 11 months 26 days
Options exercisable, weighted average remaining contractual term	8 years 3 months 21 days
Options vested or expected to vest, weighted average remaining contractual term	9 years 3 months 3 days
Options outstanding, aggregate intrinsic value	$ 620	$ 983
Options exercisable, aggregate intrinsic value	363
Options vested or expected to vest, aggregate intrinsic value	$ 257

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	87.13%	88.80%
Expected life (years)	6 years 29 days	6 years 29 days
Risk-free interest rate	2.01%	0.70%
Dividend rate	0.00%	0.00%

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 764	$ 361
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	294	168
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 470	$ 193

License Agreements - Additional

License Agreements - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Common stock, shares, issued	18,812,267	18,781,242
UABRF [Member] | Antidilution Provision [Member]
Common stock, shares, issued	151,382
Equity Method Investment, Ownership Percentage	2.50%
Raise of investment	$ 20,000,000
Emory License Agreement [Member] | UABRF [Member]
Aggregate pay for development milestones total	$ 1,400,000
License agreement description	The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.
Exclusive License Agreement [Member] | UABRF [Member]
Common stock, shares, issued	91,250
Royalties on cumulative net sales	$ 22,500,000
Exclusive License Agreement [Member] | UABRF [Member] | Maximum
Milestone payment	$ 1,400,000

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss	$ (6,145)	$ (2,363)
Cumulative dividends on convertible preferred stock	0	(706)
Net loss attributable to common stockholders	$ (6,145)	$ (3,069)
Net loss per share attributable to common stockholders – basic and diluted	$ (0.33)	$ (0.82)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	18,800,546	3,764,488

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from calculation of diluted net loss per share	0	9,993,727
Stock Options To Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from calculation of diluted net loss per share	3,013,205	1,552,290

Commitments and Contingencies (

Commitments and Contingencies (Additional Information) (Details)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Royalty term	10 years

Facility Leases - Additional In

Facility Leases - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Loss Contingencies [Line Items]
Agreement Threshold	$ 380,000	$ 301,000
Birmingham, Alabama
Loss Contingencies [Line Items]
Lease expense incurred	$ 400,000
New York [Member]
Loss Contingencies [Line Items]
Lease expiration month and year	2027-03
Office Building | Birmingham, Alabama
Loss Contingencies [Line Items]
Operating lease, term of contract	63 months
Operating lease, option to extend	option to extend five years
Maximum
Loss Contingencies [Line Items]
Agreement Threshold	$ 4,000,000
Maximum | Birmingham, Alabama
Loss Contingencies [Line Items]
Security deposit			$ 251,000
Minimum | Birmingham, Alabama
Loss Contingencies [Line Items]
Security deposit	$ 17,000,000
Equipment
Loss Contingencies [Line Items]
Leaseback transaction, description	Company had completed the sale and leaseback for four pieces of equipment and is leasing three other items directly from the leasing company. The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.
Security deposit	$ 100,000		$ 100,000
Equipment | Maximum
Loss Contingencies [Line Items]
Amount held for equipment purchases	$ 1,400,000

Facility Leases - Summary of Le

Facility Leases - Summary of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lease Cost
Amortization of finance right-of-use assets	$ 149	$ 113
Interest on finance lease liabilities	14	21
Operating lease cost	112	52
Short-term lease cost	105	115
Total lease cost	380	$ 301
Cash paid for amounts included in the measurement of lease liability – finance leases	163
Cash paid for amounts included in the measurement of lease liability – operating leases	$ 54
Weighted-average remaining lease term – finance leases	1 year 7 months 9 days
Weighted-average remaining lease term – operating leases	4 years 6 months
Weighted-average discount rate – finance leases	10.20%
Weighted-average discount rate – operating leases	10.40%

Facility Leases - Schedule of R

Facility Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Remainder of 2022	$ 286
2023	252
2024	30
2025	0
2026	0
Thereafter	0
Total lease payment	568
Less: interest	42
Total lease liability	526
Short-term financing lease liability	325	$ 392
Long-term financing lease liability	201	269
Remainder of 2022	351
2023	478
2024	490
2025	502
2026	311
Thereafter	45
Total lease payment	2,177
Less: interest	437
Total lease liability	1,740
Short-term operating lease liability	306	234
Long-term operating lease liability	$ 1,434	$ 1,515